40 results about "Lipoprotein particle" patented technology

Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and / or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and / or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL / RHDL.

Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and / or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.

The present invention is directed to methods of measuring the concentration of lipoprotein particles and / or lipoprotein-specific apolipoproteins in a biological fluid using an immunoassay, without the need of preliminary physical separation of the various types of lipoprotein particles present in the biological fluid.

Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

The system and method of the present invention relate to characterizing lipoproteins in a sample. The system includes a light source that delivers electromagnetic energy in a predetermined range of wavelengths to the sample and a sensor that senses an intensity spectrum which emerges from the sample when the sample is illuminated by the light source. A processor determines a chemical composition of the sample to determine the presence of lipoprotein particles. The processor then characterizes lipoproteins that are within in the sample by deconvoluting the intensity spectrum into a scattering spectrum and absorption spectrum. The method includes illuminating the sample with electromagnetic energy having a predetermined range of wavelengths and sensing the electromagnetic energy that emerges from the sample. The method further includes transducing the sensed electromagnetic energy which emerges from the sample into an intensity spectrum that determines the types of lipoproteins that are within the sample.

The process of producing active protein and oil with maggot and earthworm as material belongs to the field of feed producing technology. The automatic production process can produce full protein powder, granular full protein product, defatted protein powder, defatted granular protein product and separated maggot or earthworm oil. The production process can maintain the activity of the protein, amino acids and other active matter unchanged, raise the biological potency and digesting and absorbing rate of the products. The present invention also provides relevant large scale production process.

This application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and / or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and / or cardiodiabetes are also disclosed.

Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.

A method for determining the molar concentration of specific lipoprotein particles present in a bodily fluid is presented. Multipixel Capillary Isotachophoresis Laser Induced Fluorescence is applied to fluorescently-labeled lipoproteins or immunologically-labeled apolipoproteins, facilitating quantification of lipoproteins and / or lipid particles and / or their associated apolipoproteins in a sample. The measurements are used to predict the risks of developing, progressing in severity of diseases related to lipoprotein particles, including cardiovascular and metabolic disorders.

The invention relates to a process for preparing saposin lipoprotein particles, comprising a saposin-like protein, lipids and optionally a hydrophobic agent wherein the saposin-like protein or the hydrophobic agent is selectively bound to a support to allow the self-assembly of the saposin lipoprotein particles. The process of the invention comprises the step of a.) providing the hydrophobic agent and lipids, b. 1) / b.2) contacting the hydrophobic agent or the saposin-like protein with a support that is capable of selectively binding either of the two molecules to the support, c.1) / c.2) contacting the support-bound particle components with the remaining particle components, either the saposin-like protein or the hydrophobic agent, to allow fpr the self-assembly of the saposin lipoprotein particle on the support and d.) optionally eluting the support-bound saposin lipoprotein particles.

The invention relates to a detection system used for simultaneously detecting lipoprotein sub-fraction cholesterol and lipoprotein particle concentration. The detection system is characterized in thatthe system comprises a sample container, a reagent container, a cleaning fluid container, a reaction module, a first detection module and a second detection module; the sample container is connectedto the inlet pipeline of the first detection module through a pipeline; the cleaning liquid container is connected to a pipeline which is connected with the sample container and the first detection module through a pipeline; the outlet of the first detection module is connected with the inlet of the reaction module through a pipeline; the reagent container is connected to a pipeline which is connected with the first detection module and the reaction module through a pipeline; and the outlet end of the reaction module is connected with the second detection module. With the detection system adopted, lipoprotein cholesterol sub-fractions can be detected, and lipoprotein particle concentration can be also detected; and since the detection system does not need to perform detection twice, and time and cost are saved.

A concentration of cholesterol ester or free cholesterol can be calculated using the concentrations of total cholesterol and triglyceride in lipoproteins contained in a sample. Further, a concentration of lipoprotein particles in a fraction can be calculated using the lipoprotein particle size in the fraction. The concentrations of total cholesterol and triglyceride contained in a subject sample are detected. Using the concentrations of total cholesterol and triglyceride thus detected, the concentration of cholesterol ester or free cholesterol is calculated. Further, using the concentration of cholesterol ester or free cholesterol thus calculated, the concentration of lipoprotein particles in a fraction can be calculated.

This application describes a method for measuring the molar concentrations of lipoprotein particles and lipoprotein subclass particles in bodily fluid by Multipixel Capillary Isotachophoresis Laser Induced Fluorescence (MPCE-ITP-LIF) and compositional analysis of spherical lipoprotein particles. The ability to measure several kinds of lipoproteins and particles in one unified system provides a useful diagnostic tool for predicting the risk of developing metabolic diseases such as cardiovascular disease and cardiodiabetes.

The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions / vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers:a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), andb. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), andc. optionally the S antigen derived from Hepatitis B.

Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and / or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL / RHDL.

The invention relates the use of single particle light scattering, preferably interferometric scattering microscopy (also referred to herein as iSCAT), to measure the concentration of a particle in asolution. The invention furthermore relates to the use of light scattering to detect lipoprotein particles in a sample, and to related diagnostic and treatment methods.

Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

This invention relates to methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and / or phospholipid content in the lipoprotein particles. The invention also relates to the use of the assessed quantities of the lipoprotein particles or portions thereof to determine whether a subject is at increased risk for cardiovascular diseases and cardiodiabetes.

An improved method of obtaining fluorescence measurements which may be used as a measure of the CETP-catalyzed rate of transfer of a lipophilic non-polar fluorescent cholesteryl ester between lipoprotein particles is disclosed. The method may be used in assays for screening CETP inhibitors.

Non-naturally occurring lipoprotein particles, process for preparing such particles and uses thereof.

A concentration of cholesterol ester or free cholesterol can be calculated using the concentrations of total cholesterol and triglyceride in lipoproteins contained in a sample. Further, a concentration of lipoprotein particles in a fraction can be calculated using the lipoprotein particle size in the fraction. The concentrations of total cholesterol and triglyceride contained in a subject sample are detected. Using the concentrations of total cholesterol and triglyceride thus detected, the concentration of cholesterol ester or free cholesterol is calculated. Further, using the concentration of cholesterol ester or free cholesterol thus calculated, the concentration of lipoprotein particles in a fraction can be calculated.

Non-naturally occurring lipoprotein particles, process for preparing such particles and uses thereof.

The invention discloses a reagent for detecting the concentration of lipoprotein particles. The reagent is composed of the following components: a diluent, a density liquid, and a buffer, and the density liquid contains alcohols, and the alcohols The concentration of the substance is 0.1%‑50%. The invention belongs to the field of in vitro diagnosis. The invention provides a reagent for detecting the concentration of lipoprotein particles. The reagent can detect the concentration of protein particles alone, and can be used in combination with other instrument reagents to simultaneously detect lipoprotein cholesterol subcomponents without having to detect twice, saving It saves time and cost, has high commercial value, and can be widely used in clinical tests and scientific research experiments.

The invention relates to a process for preparing saposin lipoprotein particles, comprising a saposin-like protein, lipids and optionally a hydrophobic agent wherein the saposin-like protein or the hydrophobic agent is selectively bound to a support to allow the self-assembly of the saposin lipoprotein particles. The process of the invention comprises the step of a.) providing the hydrophobic agent and lipids, b. 1) / b.2 contacting the hydrophobic agent or the saposin-like protein with a support that is capable of selectively binding either of the two molecules to the support, c.1) / c.2) contacting the support-bound particle components with the remaining particle components, either the saposin-like protein or the hydrophobic agent, to allow for the self-assembly of the saposin lipoprotein particle on the support and d.) optionally eluting the support-bound saposin lipoprotein particles.

The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-like protein belonging to the SAPLIP family of lipid interacting proteins or a derivative form thereof, wherein the process comprises the steps of a) providing a mixture of crude membrane vesicles obtained from a cell or an organelle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles. The invention also provides a process for preparing a purified saposin lipoprotein particle comprising the steps of preparing a library according to the process described above and the additional step of f) purifying the saposin lipoprotein particle from the library. In addition, the invention provides a library of saposin lipoprotein particles and saposin lipoprotein particles obtainable according to the processes of the invention. These can be used in medicine, in particular in preventing, treating or lessening the severity of a disease or for use in a diagnostic method, a cosmetic treatment or for use as vaccination formulation or as a tool for drug development, drug screening, drug discovery, antibody development, development of therapeutic biologies, for membrane or membrane protein purification, for membrane protein expression, for membrane and / or membrane protein research, in particular lipidomics and proteomics, preferably for the isolation, identification and / or study of membranes and / or membrane proteins or creation of a lipidome or proteome database.

A method of identifying a subject having or at risk of having or developing a cardiovascular disease and / or a cardiovascular event, includes: measuring, in a sample obtained from the subject, at least two cardiovascular risk factors: a) sPLA2 activity and b) oxidized phospholipids on apolipoprotein B-100 particles (OxPL / apoB), combining the measurements, the combined value of sPLA2 activity and OxPL / apoB being indicative of having or a risk of having or developing a cardiovascular disease and / or cardiovascular event.